Eliminating TB Requires U.S. Leadership, Investment In Research To Develop New Vaccines, Drugs

New York Times: Eliminate the TB Scourge
Uvistra Naidoo, pediatrician and research scientist

“…Today we have an ineffective TB vaccine, insufficient diagnostic tools, TB drugs with pernicious side effects, a growing problem of bacterial resistance to current treatments, and an inexplicable lack of urgency, even though one-third of the planet’s population is infected by TB, according to the Centers for Disease Control and Prevention. … Where is the reflection of this reality in research priorities and overlying policies? … TB control and prevention have not been embraced [the way other diseases, like Ebola, have been] despite the disease’s extraordinary global impact and cost. … The world urgently needs President Obama’s leadership on this. But his global health budget request for the coming year would cut TB aid funding by 19 percent. … Drug-resistant TB can and must be confronted — but researchers and health care experts need the money to develop new vaccines and drugs…” (5/19).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.